Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse
Table 1
Baseline characteristics ( = 104).
Variables
ATVM ( = 43)
ATVM + PTVM ( = 53)
PTVM ( = 8)
Age (years)
62.3 ± 10.5
64.2 ± 10.4
63.4 ± 12.3
0.59
Parity
3.1 ± 1.0
3.3 ± 1.4
2.6 ± 1.6
0.15
Menopause
36
46
8
0.68
Diabetes mellitus
5
14
2
0.15
Prior hysterectomy
11
7
2
0.22
Prior incontinence surgery
0
4
2
0.02
Prior prolapse surgery
2
6
0
0.43
Concomitant surgeries
Midurethral sling procedure
0
0
6
<0.001
Miscellaneous
2
3
1
0.52
Operation time (minutes)
61.7 ± 21.8
118.5 ± 36.9
81.6 ± 16.9
<0.001
Blood loss (mL)
106.5 ± 129.4
133.2 ± 157.7
132.5 ± 86.3
0.23
Follow-up interval (months)
24.1 ± 7.4
21.0 ± 5.3
20.1 ± 5.8
0.06
Perioperative complications
Vaginal hematoma
1
2
0
1.00
Voiding difficulty
2
0
0
0.32
Postoperative complications
Mesh extrusion
1
3
0
0.73
Redundant anterior vaginal tissue
0
1
0
1.00
Postoperative failure
Cystocele
0
0
0
—
Uterine prolapse stage 2
0
2
0
0.57
Rectocele
0
0
0
—
ATVM = tailored anterior transvaginal mesh surgery; PTVM = tailored posterior transvaginal mesh surgery. Values are expressed as the mean ± standard deviation or patient number. By Kruskal-Wallis test, chi-square test, or Fisher’s exact test.
